First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors
France-based Transgene and BioInvent International AB announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic Vaccinia virus BT-001 had been enrolled at Institut Bergonié, located in Bordeaux, France.
By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response. Also, delivering the anti-CTLA4 antibody directly to the tumor microenvironment aims to induce local Treg depletion and strong therapeutic activity.
Consequently, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA4 antibody will be greatly improved.
Hedi Ben Brahim, Chairman, and CEO of Transgene, stated in a press release, “This first Invir.IO™ based oncolytic virus entering the clinic has been shown to induce long-lasting antitumor immune responses and abscopal effects in several preclinical tumor models; in these experiments, the activity of BT001 was further enhanced through combination with an anti-PD-1 antibody treatment. It has a unique mode of action, and the outstanding results so far indicate it could make a significant difference to cancer patients.”
Transgene (Euronext: TNG) is a publicly-traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.